Moomoo AI 已提取核心訊息
Intelligent Bio Solutions Inc. announced the completion of a 1-for-12 reverse stock split effective at 5:00 pm Eastern Time on January 26, 2024. The reverse stock split was approved by stockholders at the annual meeting on December 13, 2023, and the final ratio was determined by the Board of Directors. This action aims to increase the company's per share trading price to comply with Nasdaq's minimum share price listing requirements. As a result, the number of outstanding shares was reduced from approximately 17.93 million to approximately 1.49 million, while the number of authorized shares remains at 100 million. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of outstanding stock options, restricted stock unit...Show More
Intelligent Bio Solutions Inc. announced the completion of a 1-for-12 reverse stock split effective at 5:00 pm Eastern Time on January 26, 2024. The reverse stock split was approved by stockholders at the annual meeting on December 13, 2023, and the final ratio was determined by the Board of Directors. This action aims to increase the company's per share trading price to comply with Nasdaq's minimum share price listing requirements. As a result, the number of outstanding shares was reduced from approximately 17.93 million to approximately 1.49 million, while the number of authorized shares remains at 100 million. Proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise or vesting of outstanding stock options, restricted stock unit awards, and warrants. The company's common stock began trading on a split-adjusted basis on January 29, 2024, under the same trading symbol 'INBS' and a new CUSIP number. No fractional shares were issued; stockholders who would have received a fractional share were rounded up to the nearest whole number. Intelligent Bio Solutions Inc. is a medical technology company focused on delivering rapid, non-invasive testing solutions, including a drug screening system through fingerprint sweat analysis.
Intelligent Bio Solutions Inc.宣佈完成每12人1比12的反向股票拆分，將於美國東部時間2024年1月26日下午5點生效。在2023年12月13日的年會上，股東批准了反向股票拆分，最終比率由董事會確定。該行動旨在提高公司的每股交易價格，以符合納斯達克的最低股價上市要求。結果，已發行股票數量從約1,793萬股減少到約149萬股，而授權股票數量仍爲1億股。對每股行使價和行使或歸屬未行使股票期權、限制性股票單位獎勵和認股權證時可發行的股票數量進行了相應的調整。該公司的普通股於2024年1月29日開始按拆分調整後的基礎上交易，交易代碼相同 “INBS” 和新的CUSIP編號。沒有發行零碎股票；本來可以獲得小數份額的股東四捨五入到最接近的整數。Intelligent Bio Solutions Inc. 是一家醫療技術公司，專注於提供快速、非侵入性的測試解決方案，包括通過指紋汗液分析的藥物篩選系統。
Intelligent Bio Solutions Inc.宣佈完成每12人1比12的反向股票拆分，將於美國東部時間2024年1月26日下午5點生效。在2023年12月13日的年會上，股東批准了反向股票拆分，最終比率由董事會確定。該行動旨在提高公司的每股交易價格，以符合納斯達克的最低股價上市要求。結果，已發行股票數量從約1,793萬股減少到約149萬股，而授權股票數量仍爲1億股。對每股行使價和行使或歸屬未行使股票期權、限制性股票單位獎勵和認股權證時可發行的股票數量進行了相應的調整。該公司的普通股於2024年1月29日開始按拆分調整後的基礎上交易，交易代碼相同 “INBS” 和新的CUSIP編號。沒有發行零碎股票；本來可以獲得小數份額的股東四捨五入到最接近的整數。Intelligent Bio Solutions Inc. 是一家醫療技術公司，專注於提供快速、非侵入性的測試解決方案，包括通過指紋汗液分析的藥物篩選系統。
有用
沒用